We have screened 58 dogs for the study. None of the dogs were enrolled due to the detection of metastatic disease during the screening process. Two other dogs were not screened due to the prior use of Yunnan Baiyao beyond the 24-hour limit allowed, and another owner cancelled the morning of the screening for unknown reasons. We have enrolled 19 dogs to date, bringing enrollment to 95% of the dogs proposed for the study. We have recorded an adverse event (2-3 episodes of fainting/collapse) attributed to propranolol in one dog (MN02), which developed approximately 6 months into the treatment protocol. The issue was resolved by reducing the dose of propranolol to 1.0 mg/kg. We are continuing to enroll dogs in the highest dose cohort (1.3 mg/kg) as this adverse event fell outside of the 21-day assessment period used to define the dose escalation criteria. Our goal is to enroll the final dog in the study in the next few months.
For the PK studies in Milestone 2, we have completed the propranolol and doxorubicin PK analysis for all dogs enrolled to date.
Overall, five dogs enrolled in the study have lived more than nine months (26%), and four dogs have survived more than one year (21%). Of the 4 dogs that have survived for more than one year, two of these dogs have survived for over three years, one dog has survived for just over two year, and the other just under two years.
Presentations:
An overview of the study was presented at the 12th Biennial AKC Canine Health Foundation National Parent Club Canine Health Conference (NPCCHC) held August 9-11, 2019 in St. Louis, MO
A summary of the study design and goals was given at the annual Veterinary Cancer Society meeting held November 4-6, 2021 (virtual meeting). The presentation was part of a special session on hemangiosarcoma.
A summary of the study design and pre-clinical data supporting the rationale for the study were presented to the Minnesota Veterinary Medical Association at their annual meeting, held February 10-11, 2022 (virtual meeting).
An overview and preliminary analysis of the study was presented at the College of Veterinary Medicine
faculty, staff, and students at the University of Minnesota as part of the Grand Rounds seminar series
on December 1, 2022 (virtual presentation).
